Eris Lifesciences Ltd

Eris Lifesciences Limited: Trading Window closed from October 01, 2026 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and half year ending on September 30, 2026, to the public.

AGM details

• Date: 25 September 2026; start time 11:00 AM; mode: VC/OAVM.
• End time: 11:30 PM.
• Record date: 18 August 2026.

Resolutions and outcomes

• Item 1 (Ordinary): Adopt standalone and consolidated financial statements for year ended March 31, 2026.
• Outcome: Passed; 99.997% in favour.
• Item 2 (Ordinary): Re-appoint Kaushal Shah after retirement by rotation.
• Outcome: Passed; 99.26% in favour.
• Item 3 (Ordinary): Ratify remuneration of Cost Auditors for FY ending March 31, 2027.
• Outcome: Passed; 100% in favour.
• Item 4 (Special): Re-appoint Sujesh Vasudevan as Independent Director.
• Outcome: Passed; 97.67% in favour.

Dividend

• Dividend: not proposed or declared.

Director changes

• Re-appointment of Kaushal Shah as director (retiring by rotation).
• Re-appointment of Sujesh Vasudevan as Independent Director.

Auditors

• Remuneration of Cost Auditors ratified for FY ending March 31, 2027.

Material related party transactions

• No material related party transactions disclosed.

AGM details and resolutions

• AGM held via Video Conferencing on 25 September 2026 from 11:00 to 11:30 AM.
• Ordinary: To adopt Audited Standalone and Consolidated Financial Statements for FY ended 31 March 2026.
• To re-appoint Kaushal Kamlesh Shah, retiring by rotation, who offers himself for re-appointment.
• To ratify remuneration of Cost Auditors for FY ending 31 March 2027.
• To re-appoint Sujesh Vasudevan as Independent Director.
• Voting results will be disclosed separately to the Stock Exchanges.
• AGM commenced 11:00 AM and concluded 11:30 AM.

Allotment Details

• Allotted 1,55,264 equity shares on Sep 22, 2026 under ESOP-2021.
• Grant-year breakdown: 2022, 66,422 shares at Rs 557.24 per share.
• 2023 and 2024 add 57,239 shares at Rs 510.32 and 31,603 at Rs 728.16.
• Paid-up capital increased from ₹13,85,83,305 to ₹13,87,38,569.

Appointment: Akhil Awasthi as Additional Director

• Type: appointment as Additional Director (Non-executive, Independent).
• Name and designation: Akhil Awasthi, Additional Director (Non-executive, Independent).
• Effective from 26 September 2026; 5-year term, subject to member approval.
• Reason: recommended by Nomination and Remuneration Committee; board approved via circular resolution.
• Profile: seasoned investment professional with over 30 years in private equity and healthcare.
• Relationship: not related to any director.
• Debarment: not debarred by SEBI or other authorities.

Resignation of ED & COO

• Resignation of Krishnakumar Vaidyanathan as Executive Director & COO; effective Sep 30, 2026, to pursue opportunities outside.

Clarification on loan value

• Company states loan value is the amount disclosed in its September 9, 2026 disclosure.
• Readers should rely on exchange-disseminated information from the company.

Parties to the agreement

• Axis Bank Limited (lender) and Eris Lifesciences Limited (borrower).

Purpose

• Draw down a term loan of ₹45 crore to meet other liabilities.

Key terms

• Term loan amount ₹45 crore; bank to have a charge on the Company's brands; executed 09 September 2026.

Related party status

• Not a related party transaction; no promoter/group linkage disclosed.

Impact on business/finances

• No expected impact on Net Debt for the quarter; routine financial adjustment.

Regulatory disclosures / governance

• Regulatory intimation under SEBI LODR filed; no board changes disclosed.

Meeting Details

• Date and time: 10 September 2026 at 3:30 PM IST; one-to-one in-person meeting.
• Organizer: Analyst and Institutional Investor Meeting with Bank of India Mutual Fund.

Participants

• Company management representatives: Eris Lifesciences to participate in the meeting.

Purpose

• Purpose: Analyst/institutional investor interaction; discussion based on publicly available documents.